Liver TransplantationNCT07247877
Research on Using Small-for-size Grafts for Auxiliary Liver Transplantation in the Treatment of Portal Hypertension
An observational study of Liver Transplantation, run by Zhi-Jun Zhu.
Trial summary
The objective of this observational study is to compare the safety profile of auxiliary liver transplantation using small-for-size grafts with that of conventional liver transplantation and to evaluate the efficacy of this technique. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Liver Transplantation
- How many people
- 396 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2014to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with cirrhotic portal hypertension who were treated at the Liver Transplantation Center of Beijing Friendship Hospital, Capital Medical University between January 2014 and December 2028, and who underwent either auxiliary liver transplantation using small-for-size grafts (study group) or conventional liver transplantation (control group).
Who may be able to join
- Age > 14 years.
- Presence of decompensated portal hypertension.
- Meeting the indications for liver transplantation surgery.
- International Normalized Ratio (INR) < 2.4.
- Scheduled to undergo orthotopic auxiliary partial liver transplantation or conventional liver transplantation.
Who cannot join
- Rare liver-related anatomical variations.
- Presence of contraindications to liver transplantation combined with malignant tumors.
- Grade III or higher portal vein thrombosis.
- Severe systemic diseases unrelated to the etiology or complications of portal hypertension.
- Special surgical procedures such as dual-graft liver transplantation.
- Special graft sources including domino liver transplantation.
- Liver re-transplantation.
About this study
Official title: Innovative Technology Research on Using Small-for-size Grafts for Auxiliary Liver Transplantation in the Treatment of Portal Hypertension
The objective of this observational study is to compare the safety profile of auxiliary liver transplantation using small-for-size grafts with that of conventional liver transplantation and to evaluate the efficacy of this technique. The primary research question it seeks to investigate is:
"What are the differences in safety and efficacy between auxiliary liver transplantation utilizing small-for-size grafts and conventional liver transplantation for the treatment of portal hypertension?"
- Conditions
- Liver Transplantation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| auxiliary liver transplantation using small-for-size grafts | Not described | |
| conventional liver transplantation using Standard-size graft | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival
Measured: Within one year after liver transplantation
Complications
Measured: Within one year after liver transplantation
portal hypertension resolution
Measured: Within one year after liver transplantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2025
- Study start1 Jan 2014
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 396 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhi-Jun Zhu
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Zhi-Jun Zhu, Beijing Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07247877
- Sponsor's protocol ID
- BFHHZML20250022
- Status last verified
- Jan 2026
- First submitted
- 18 Nov 2025
- Last updated
- 20 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Innovative Technology Research on Using Small-for-size Grafts for Auxiliary Liver Transplantation in the Treatment of Portal Hypertension
- ClinicalTrials.gov ID
- NCT07247877
- Acronym / sponsor ID
- BFHHZML20250022
- Conditions
- Liver Transplantation
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 396 participants (estimated)
- Lead sponsor
- Zhi-Jun ZhuUniversity, hospital or other
- Study start
- 1 Jan 2014 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 25 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observational study is to compare the safety profile of auxiliary liver transplantation using small-for-size grafts with that of conventional liver transplantation and to evaluate the efficacy of this technique. The primary research question it seeks to investigate is:
"What are the differences in safety and efficacy between auxiliary liver transplantation utilizing small-for-size grafts and conventional liver transplantation for the treatment of portal hypertension?"
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| auxiliary liver transplantation using small-for-size grafts | – | – |
| conventional liver transplantation using Standard-size graft | – | – |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with cirrhotic portal hypertension who were treated at the Liver Transplantation Center of Beijing Friendship Hospital, Capital Medical University between January 2014 and December 2028, and who underwent either auxiliary liver transplantation using small-for-size grafts (study group) or conventional liver transplantation (control group).
Key inclusion criteria (5 listed)
- Age > 14 years.
- Presence of decompensated portal hypertension.
- Meeting the indications for liver transplantation surgery.
- International Normalized Ratio (INR) < 2.4.
- Scheduled to undergo orthotopic auxiliary partial liver transplantation or conventional liver transplantation.
Key exclusion criteria (7 listed)
- Rare liver-related anatomical variations.
- Presence of contraindications to liver transplantation combined with malignant tumors.
- Grade III or higher portal vein thrombosis.
- Severe systemic diseases unrelated to the etiology or complications of portal hypertension.
- Special surgical procedures such as dual-graft liver transplantation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
overall survival
Time frame: Within one year after liver transplantation
Complications
Time frame: Within one year after liver transplantation
portal hypertension resolution
Time frame: Within one year after liver transplantation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
- Individual participant dataSharing planned: No
Related trials for Liver Transplantation
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
Not yet recruiting
Hypothermic Oxygenated Machine PErfusion During Ex-vivo SPLITting in Liver Pediatric Transplantation (HOPESPLIT)
Pediatric Liver Transplantation
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Recruiting
Multidisciplinary Non-Pharmacological Intervention to Improve Quality of Life in Solid Organ Transplant Recipients
Heart Transplant Patients, Kidney Transplant Patients
Not yet recruiting
RAPID for Unresectable Colorectal Liver Metastases
Colorectal Liver Metastases (CRCLM), Colorectal Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Transplantation, run by Zhi-Jun Zhu.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival (time frame: Within one year after liver transplantation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.